The global hormonal contraceptive market size was estimated at USD 16.14 billion in 2023 and is projected to reach USD 21.21 billion by 2030, growing at a CAGR of 4.01% from 2024 to 2030. The market’s growth is being driven by increasing awareness in emerging economies regarding hormonal contraception methods, growing investments by major players in RD for novel contraceptive devices, and supportive initiatives by governments aimed at improving access to contraceptive products. The rising awareness among women about various available options to prevent unintended pregnancies is also expected to further propel industry growth.
The World Health Organization (WHO) has provided guidelines for the use of hormonal contraceptives, including progestogen injectables, intrauterine devices (IUDs), and implants, particularly for women at higher risk of HIV infection. These guidelines were based on the Evidence for Contraceptive Options and HIV Outcomes (ECHO) trial, which demonstrated no significant differences in HIV acquisition among women using hormonal versus non-hormonal contraceptives, such as levonorgestrel implants, copper IUDs, or DMPA-IM.
Additionally, key market players are strengthening their presence through strategies such as increased research and development investments and commercializing new products. For example, in July 2023, Perrigo Company plc or its affiliates received FDA approval for Opill (norgestrel) tablets for nonprescription use in the U.S. This approval enables customers to purchase this progestin-only pill without a prescription at convenience stores, drug stores, grocery stores, and online platforms, offering a more accessible option for birth control. Such strategies are anticipated to increase the demand for over-the-counter (OTC) hormonal contraceptives, thereby supporting the overall growth of the global market.
Key Market Trends Insights:
• In 2023, the North American hormonal contraceptive market accounted for the largest revenue share of 45.41%, making it the leading regional market globally. Within North America, the U.S. held the largest share, reflecting strong consumer awareness, well-established healthcare infrastructure, and easy access to a variety of contraceptive options.
• When analyzed by method, the pill segment led the market, capturing a revenue share of 47.44% in 2023. This dominance underscores the pill’s popularity as a convenient, widely available, and reliable form of hormonal contraception for women.
• In terms of hormone type, the combined hormone contraceptive segment dominated the market in 2023, accounting for a revenue share of over 73%. This highlights the strong preference among consumers for contraceptives that combine estrogen and progestin, offering enhanced effectiveness and flexibility for preventing pregnancy.
Order a free sample PDF of the Hormonal Contraceptive Market Intelligence Study, published by Grand View Research.
Market Size Forecast:
• 2023 Market Size: USD 16.14 Billion
• 2030 Projected Market Size: USD 21.21 Billion
• CAGR (2024-2030): 4.01%
• North America: Largest market in 2023
Key Companies Market Share Insights:
The hormonal contraceptive market is considered moderately consolidated, primarily due to the presence of several generic drug manufacturers competing alongside branded product companies. To strengthen their market position, industry participants are focusing on strategies such as the approval and commercialization of new products, expanding their geographical reach, and broadening the application scope of existing products.
In addition, to maintain a competitive edge, companies are actively adopting a range of strategic initiatives, including collaborations, acquisitions, partnerships, and the launch of innovative products. These strategies not only help in enhancing market share but also enable companies to respond effectively to changing consumer preferences, regulatory requirements, and evolving market dynamics in the global hormonal contraceptive industry.
Key Players
• AbbVie Inc.
• Afaxys, Inc.
• Teva Pharmaceuticals Industries Ltd.
• Bayer AG
• Organon Group of Companies
• Pfizer
• Agile Therapeutics
• Janssen Pharmaceuticals Inc.
• Lupin Pharmaceuticals Inc.
• Pregna International Ltd.
Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.
Conclusion:
The global hormonal contraceptive market is experiencing steady growth, driven by increasing awareness in emerging economies, significant investments in research and development by key players, and supportive government initiatives aimed at enhancing access to contraceptive products. The market is characterized by a moderate level of consolidation, with several generic drug manufacturers contributing to the competitive landscape. Strategic approaches such as product approvals, geographical expansion, and broadening the application scope of existing products are being adopted by industry participants to enhance their market share.
